Algeria MIPH Medical Device Import Teardown: 327 Approved Importers

A quantitative teardown of Algeria's MIPH list of 327 approved medical device importers, analyzing the SARL-dominated legal mix and Decree 24/22 reforms.

Understanding Algeria's Medical Device Import Authorization Model

Algeria represents one of the largest and most dynamically evolving healthcare markets in North Africa. With a population of approximately 46 million and a government committed to expanding domestic healthcare infrastructure under its national development plans, the country offers significant commercial opportunities for international medical device and IVD manufacturers.

However, entering the Algerian market requires navigating a highly centralized, strict import-control regime. Unlike neighboring Morocco, which utilizes a lighter activity-declaration model, Algeria mandates that all medical devices imported into the country go through an establishment licensed specifically for importation.

This teardown provides a detailed quantitative analysis of the official register of approved pharmaceutical and medical device import establishments published by the Algerian Ministry of Pharmaceutical Industry (Ministère de l'Industrie et de la Production Pharmaceutique, MIPH). Based on the official register (dated March 12, 2026), we break down the structure of the Algerian importer landscape, analyze corporate legal-form distributions, detail the split between medical device-only and pharmaceutical-device agreements, and examine the profound market-access implications of recent regulatory updates, including Ministerial Decree No. 24 and Decree No. 22.

The Importer Landscape: 327 Approved Establishments

Under Algerian healthcare law—specifically Law No. 18-11 of July 2, 2018, which governs health products—foreign manufacturers are prohibited from importing medical devices directly. They must appoint a licensed local Algerian company to act as their importer of record and local representative.

A quantitative analysis of the MIPH registry reveals a highly consolidated channel for medical device imports:

Total Import Establishment Records: 327
Unique Approved Importer Entities: 326
Specialized Device-Only (DM) Licenses: 307
Combined Pharma & Device (PP+DM) Licenses: 20

This small number of approved entities (326 unique companies) represents the entire legal gateway for medical device imports into Algeria. For international manufacturers, this means that partner pre-qualification is a critical strategic task. The market has a limited pool of approved operators, and the vast majority of these operators are small-to-medium private enterprises.

The Regulator Split: MIPH vs. ANPP

A common point of confusion for regulatory affairs teams is the division of authority between the two primary healthcare regulators in Algeria:

MIPH (Ministère de l'Industrie et de la Production Pharmaceutique): Oversees industrial policy, pharmaceutical manufacturing, and the licensing of economic operators (importers, distributors, and manufacturers). MIPH issues the Agrément d'Importation (Import Establishment Authorization) analyzed in this teardown.
ANPP (Agence Nationale des Produits Pharmaceutiques): An autonomous agency established under Law 18-11 that sits under the Ministry of Health (MSPRH). ANPP is responsible for technical product registration, issuing marketing authorizations (Décision d'Enregistrement), quality control testing, and clinical trial authorizations.

To place a medical device on the Algerian market, a manufacturer must secure a product registration from the ANPP (valid for 5 years), but the physical shipment must clear customs through an importer holding a valid MIPH import authorization.

Legal-Form Analysis: SME Domination of the Import Channel

Analyzing the corporate structure of the 327 approved importer records reveals a market dominated by private, closely held small-and-medium enterprises (SMEs). Large public corporations or multinational subsidiaries are virtually absent from the direct import registry.

The legal forms of the approved establishments are broken down as follows:

Legal Form	French Term / Meaning	Count of Records	Share of Registry
SARL	Société à Responsabilité Limitée (Limited Liability Company)	222	67.9%
EURL	Entreprise Unipersonnelle à Responsabilité Limitée (Single-Member LLC)	92	28.1%
SPA	Société par Actions (Joint-Stock Company)	11	3.4%
EPIC	Établissement Public à Caractère Industriel et Commercial (State Enterprise)	1	0.3%
INSTITUT	Public Scientific/Medical Institute	1	0.3%
Total		327	100.0%

The Dominance of LLCs (SARL & EURL)

Combined, SARLs and EURLs account for 96.0% of all approved medical device import licenses (314 out of 327).

SARL (67.9%): The standard limited liability corporate form in Algeria, requiring at least two shareholders. These represent private local distributors, family-owned commercial entities, or partnerships.
EURL (28.1%): A unique single-member limited liability company structure. This highlights that nearly 30% of Algeria’s medical device import channel is run by individual proprietors or sole-operator businesses.

For foreign medical device manufacturers, this high concentration of SARLs and EURLs indicates that local partners are likely to have a lean administrative structure. While this allows for rapid decision-making, it also means that these entities may have limited financial capacity to hold large inventories, absorb exchange rate fluctuations, or fund extensive clinical marketing campaigns.

The Role of Joint-Stock Companies (SPA)

Only 11 establishments (3.4%) are structured as SPAs (Sociétés par Actions). The SPA is the corporate vehicle of choice for larger organizations in Algeria, requiring a minimum share capital of 5,000,000 DZD (approx. USD 37,000) and a formal board of directors.

A review of the 11 SPAs in the registry shows that these represent major local pharmaceutical and medical groups. Examples include:

SPA Biopharm Distribution (Reghaia): One of Algeria's largest pharmaceutical logistics and distribution groups, with extensive national coverage.
SPA El Kendy Industrie du Médicament: A major local pharmaceutical manufacturer and distributor with advanced logistical infrastructure.
SPA Sopharmal: A prominent local pharmaceutical manufacturing and commercialization company.
SPA Dimed: A large specialized medical equipment distributor focusing on imaging, surgery, and hospital installations.
SPA Medconnect Corporation: A key distributor of high-end specialized medical devices and implants.
SPA Jamjoom Algeria Lil Dawa: A joint venture pharmaceutical and medical distributor.
SPA Union Pharmaceutique Constantinoise Distribution (UPCD): A major distributor serving the eastern region of Algeria.

These SPAs typically possess extensive warehousing capacity, cold-chain logistics, and dedicated regulatory affairs teams. However, because they are often aligned with massive pharmaceutical portfolios, smaller medical device manufacturers may find it difficult to gain mindshare or active commercial focus within these large organizations.

Public-Sector Outliers: EPIC and INSTITUT

The registry contains exactly one EPIC and one INSTITUT, representing state-channel supply mechanisms:

EPIC Office National des Appareillages et Accessoires pour Personnes Handicapées (ONAAPH): A state-owned industrial and commercial entity responsible for manufacturing and importing orthopedic appliances, prosthetics, and accessories for disabled persons. ONAAPH operates a network of distribution centers across Algeria and represents a major public procurement channel.
Institut Pasteur d'Algérie (IPA): The national public health institute. IPA is responsible for importing vaccines, diagnostic reagents, and specialized IVD equipment used in national screening and public laboratory networks.

Agreement-Code Analysis: Specialized vs. Combined Importers

Every import authorization issued by the MIPH specifies the scope of products the establishment is permitted to import. In the medical device sector, this is categorized under two agreement codes:

DM (Dispositifs Médicaux): Permits the importation of medical devices and IVDs only.
PP+DM (Produits Pharmaceutiques + Dispositifs Médicaux): Permits the importation of both pharmaceutical products and medical devices.

The distribution of these agreements across the 327 registry records is heavily skewed toward specialized operators:

DM (Devices-Only) Agreement: 307 records (93.9%)
PP+DM (Pharma & Devices) Agreement: 20 records (6.1%)

Why the DM vs. PP+DM Split Matters

This split has major strategic implications for market entry:

Targeted Competency: 93.9% of the licensed importers are specialized exclusively in medical devices. They focus their operations, sales forces, and technical engineers on hardware, consumables, and software rather than pharmaceuticals. This is highly beneficial for manufacturers of complex medical equipment (such as imaging systems or surgical robots) that require dedicated installation, calibration, and maintenance.
Pharma-Led Portfolios: The 20 companies holding PP+DM licenses are primarily large pharmaceutical distributors (such as Biopharm, El Kendi, and Aldaph). While they have massive reach and established relationships with hospital pharmacies, they often treat medical devices as secondary products to their core pharmaceutical business. Manufacturers of commodity consumables or drug-device combination products may find these partners attractive, but makers of high-tech devices may find their technical needs underserved.

The New Regulatory Paradigm: Decrees No. 24 and No. 22

Algeria’s regulatory environment underwent a major structural change in late 2025. Two new decrees were issued to clean up the import and distribution channels, eliminate shell companies, and enforce strict local quality standards.

Ministerial Decree No. 24 (Effective October 1, 2025)

Ministerial Decree No. 24 introduces a completely revised framework for licensing pharmaceutical and medical device import establishments. Its key mandates include:

2-Year License Validity: Import authorizations are no longer indefinite. They are valid for exactly two years and are subject to renewal only after a successful on-site inspection by the Ministry's regulatory officers.
Mandatory Online Directory: The Ministry is mandated to maintain and publish a live, certified online list of authorized importers to prevent the use of fraudulent licenses at customs.
Annual Reporting Requirement: Licensed importers must submit an annual import activity report to the Ministry by January 31st of the following year. This report must detail the volumes, values, and origins of all imported health products.
Strict Pharmacist Oversight: Every import establishment must employ a qualified "Directeur Technique" (Technical Director) who must be a licensed pharmacist with a registered degree. This pharmacist is personally and legally liable for the quality and compliance of the imported products.

Ministerial Decree No. 22 (Effective September 30, 2025)

Decree No. 22 targets the wholesale distribution layer of the supply chain. In Algeria, many importers also act as wholesale distributors. Under this decree:

All wholesale distribution establishments must apply for a new wholesale license.
They must establish compliant storage facilities, temperature-controlled logistics, and ISO-aligned quality systems.
The Compliance Clock: Existing distribution establishments must align their facilities and submit their compliance application files by September 30, 2026. Failure to meet this deadline will result in the suspension of their distribution rights, which would effectively halt an importer's ability to sell products locally.

Technical Specifications: The Import Agrément Application Checklist

For local establishments seeking to obtain or renew their import authorization (Agrément) from the MIPH under Decree No. 24, the application process is rigorous. The Ministry requires a complete technical dossier to verify that the importer has the administrative, technical, and operational capacity to handle medical devices.

The mandatory application dossier includes:

Administrative Documents:
- A formal application letter addressed to the Minister.
- A certified copy of the company's Commercial Register (Registre du Commerce), which must explicitly include the medical device import activity code.
- The company's articles of association (Statuts de la Société) detailing its legal form (SARL, EURL, SPA).
- A clean tax certificate (Extrait de Rôle) showing no outstanding fiscal debts.
- Proof of financial capacity (such as bank references or audited statements).
Technical Staff Dossier:
- A certified copy of the Technical Director's pharmacy diploma.
- Proof of registration of the Technical Director with the National Order of Pharmacists (Conseil National de l'Ordre des Pharmaciens, CNOP).
- An employment contract showing a full-time commitment of the Technical Director.
- A written, signed declaration of personal and legal liability by the Technical Director.
Facility and Operational Dossier:
- A certified property deed or a long-term lease agreement for the storage warehouse.
- Official zoning certificate showing the facility is in an authorized commercial/industrial zone.
- A detailed layout diagram (Plan de Masse) of the warehouse, signed by an architect, showing dedicated areas for reception, storage, quarantine, and shipping.
- A fire safety compliance certificate issued by the Civil Protection (Protection Civile).
- A detailed description of the temperature monitoring systems, cold-chain capacity, and humidity control mechanisms.
- The Standard Operating Procedures (SOPs) for product recall, counterfeit detection, and complaint handling.

This extensive checklist makes it very difficult for new, inexperienced operators to obtain an import license. Consequently, foreign manufacturers should prioritize working with established importers that already hold a valid, active Agrément rather than attempting to sponsor a new operator through this process.

Operational QMS Requirements: Temperature Tracking & Depot Controls

Under both Decree No. 24 (for importers) and Decree No. 22 (for wholesale distributors), the operational requirements for QMS and depot controls have been significantly increased. Importers must demonstrate that they maintain the physical integrity of medical devices from the moment they land in Algeria until they reach the clinical end-user.

Warehouse Zoning and Depot Controls

MIPH inspectors enforce strict rules regarding warehouse layouts. A compliant medical device depot must feature:

Separation of Products: Medical devices must be physically separated from any pharmaceutical products (for PP+DM holders).
Quarantine Areas: A secure, locked quarantine zone must exist for products that are expired, damaged, recalled, or pending ANPP registration verification.
Sanitation Protocols: The depot must have documented pest control and cleaning protocols, with records maintained for at least five years.

Temperature and Humidity Tracking

For temperature-sensitive devices, sterile consumables, and IVD reagents:

Active Monitoring: Depots must be equipped with calibrated digital data loggers that record temperature and humidity at hourly intervals.
Mapping Studies: The importer must perform periodic temperature mapping studies of the warehouse to identify "hot spots" and ensure uniform cooling.
Back-Up Power: For cold-chain products (2°C to 8°C or frozen), the facility must have a backup generator system capable of operating for at least 48 hours during a power failure.
Calibration Records: All temperature sensors, refrigerators, and air conditioning systems must undergo annual calibration by a certified third-party testing body, with calibration certificates kept on file.

License Transfer Rules and Regulatory Disputes

Appointing a local importer is a major strategic decision. If a manufacturer decides to terminate a distributor agreement or change partners, transferring the product registration and import authorizations can be complex.

Registration Transfer Process

In Algeria, the ANPP product registration (Décision d'Enregistrement) is closely linked to the local representative who submitted the application. To transfer a registration to a new importer:

The Waiver Letter (Lettre de Désistement): The manufacturer must obtain a formal, notarized waiver letter from the current registration holder, stating that they agree to transfer their rights to the new partner.
ANPP Submission: The manufacturer and the new importer submit a transfer application to the ANPP, including the waiver letter, the new importer's valid MIPH Agrément, and an updated local representation contract.
Technical Review: The ANPP reviews the application to ensure that the technical file remains unchanged and that the new importer is fully qualified.

Resolving Disputes

If the current importer refuses to sign a waiver letter (which often happens during contract disputes):

The registration cannot be transferred easily. The manufacturer may have to wait for the 5-year registration certificate to expire and then submit a completely new registration dossier with the new partner, resulting in significant market-access delays.
The Contractual Safeguard: To prevent this "registration lock-in," manufacturers must include strict clauses in their initial distributor agreements. These clauses must require the distributor to sign the ANPP waiver letter immediately upon contract termination, with financial penalties or dispute resolution clauses (such as arbitration under ICC rules in Paris or Geneva) for non-compliance.

Local-Importer Selection Step-by-Step Workflow

To manage market access in Algeria successfully, manufacturers should execute the following partner qualification process:

Identify Candidate Importer: Screen local Algerian distributors based on territory coverage, sales capacity, and medical specialty fit.
Check MIPH Registry and Agreement Code: Verify that the candidate is listed on the official MIPH approved-importer registry and holds the correct agreement code (DM for devices-only or PP+DM for pharma+devices).
Verify License Validity: Request the candidate's physical Agrément and confirm it has been issued or renewed within the last 2 years (subject to Decree No. 24).
Audit Technical Director and Depot Quality: Verify they employ a full-time licensed pharmacist as Technical Director and that their depot complies with temperature logging and storage controls.
Verify Decree No. 22 Status: Confirm the distributor has submitted their alignment file for the September 30, 2026, wholesale distribution deadline.
Cross-Reference Product Registration: Ensure the partner can support the 5-year ANPP product registration process.
Finalize Agreement: Execute the local representation and distributor contract, including clear registration transfer clauses.

North Africa Regulatory Comparison: Algeria vs. Morocco vs. Tunisia

For regional business directors, comparing the regulatory frameworks across the Maghreb countries is essential for budget allocation and timeline planning.

Parameter	Algeria (MIPH / ANPP)	Morocco (AMMPS)	Tunisia (DPM / ANMPS)
Primary Model	Heavy Import Licensing + Product Registration	Activity Declaration + Product Registration	Product Registration + Public Import Monopoly
Local Entity Requirement	Licensed Importer of Record (MIPH Authorized)	Declared Local Representative	Authorized Local Agent
Product Registration Validity	5 Years	5 Years	5 Years
Average Registration Timeline	Case-by-case	120 days (MD) / up to 12 months (IVD)	30 days–16 weeks (official)
Standard Official Fee	Variable based on dossier type	~USD 111 (MD) / ~USD 56 (IVD)	Varies
Serialization Mandate	Mandatory GS1 DataMatrix (Jan 1, 2027)	Under Consideration (No active mandate)	Voluntary / Pending legislation
Labeling Languages	French and Arabic mandatory	French and/or Arabic (Consumer devices)	French and/or English

Frequently Asked Questions

How many establishments are approved to import medical devices into Algeria?

As of the March 12, 2026 registry update, there are 327 approved pharmaceutical and medical device import establishment records, representing 326 unique companies authorized by the Ministry of Pharmaceutical Industry (MIPH).

Do I need a local Algerian importer to register and import a medical device?

Yes. Foreign manufacturers cannot hold import authorizations or product registrations directly. You must appoint a licensed local Algerian importer to act as your local representative, manage the ANPP registration dossier, and handle the physical importation and customs clearance of your products.

What is the difference between a DM and a PP+DM import agreement in Algeria?

A DM (Dispositifs Médicaux) agreement (held by 307 importers) restricts the company to importing only medical devices and IVDs. A PP+DM (Produits Pharmaceutiques + Dispositifs Médicaux) agreement (held by 20 importers) permits the importation of both pharmaceuticals and medical devices.

How long is an Algerian import-establishment authorization valid after Decree No. 24?

Under Ministerial Decree No. 24 (effective October 1, 2025), import authorizations are valid for exactly two years and must be renewed following a physical inspection of the facility by the Ministry of Pharmaceutical Industry.

Strategic Summary for Market Entry

Algeria’s medical device import channel is tightly controlled, structured, and undergoing significant regulatory tightening. With only 326 unique licensed companies—over 96% of which are small-to-medium SARLs or EURLs—manufacturers must move away from transactional distributor relationships.

To succeed:

Differentiate the Regulators: Do not conflate the product registration process (ANPP) with the operator import license (MIPH). You need both.
Verify Compliance Status: Audit prospective partners for active compliance with Decree No. 24 (2-year license validity) and Decree No. 22 (wholesale-distribution alignment due by September 30, 2026).
Prepare Packaging Early: Begin aligning your production lines for the January 1, 2027 GS1 serialization mandate.

By conducting rigorous due diligence against the official registries, international MedTech companies can secure compliant, capable partners, protecting their market access and ensuring long-term commercial success in North Africa.

Disclaimer: This analysis is based on the official register of approved pharmaceutical import establishments published by the Algerian Ministry of Pharmaceutical Industry (MIPH) on March 12, 2026. Regulatory requirements are subject to change. Manufacturers should consult with qualified local regulatory affairs counsel before signing distributor agreements or submitting product dossiers.

For cross-Maghreb regulatory contexts, see our North Africa medical device registration: Morocco, Algeria & Tunisia guide. Sibling country register analyses are available at the Tunisia DPM medical device registry analysis and Egypt EDA medical device register analysis.